Online inquiry

IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10356MR)

This product GTTS-WQ10356MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10356MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4138MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ6185MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ2949MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ7597MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ4598MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ2087MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ8354MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ7007MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW